Ustekinumab and IL-23 biologics
Biologics that block interleukin-23, a key inflammation signal in Crohn’s and colitis. An IV start, then injections every 4 to 8 weeks, with a good safety record.
Quick answer: Ustekinumab blocks IL-12 and IL-23; risankizumab, mirikizumab and guselkumab block IL-23 only. They work in Crohn’s disease and ulcerative colitis, including after anti-TNF failure. In the SEQUENCE trial, risankizumab outperformed ustekinumab for endoscopic remission in Crohn’s after anti-TNF failure.
At a glance
- For
- Moderate to severe Crohn’s disease and ulcerative colitis
- Works
- Effective, including in people who didn’t respond to anti-TNF drugs
- Cost
- PBS-subsidised for moderate to severe IBD under specialist (gastroenterologist) criteria
- Kicks in
- 4 to 12 weeks
- Dose
- IV induction (1 to 3 infusions), then under-skin injections every 4 to 8 weeks depending on the drug
- Watch for
- Colds, headache, injection-site reactions; liver tests with risankizumab
Signal blockers with a long interval.
Brand names
- Ustekinumab: Stelara and biosimilars. Risankizumab: Skyrizi. Mirikizumab: Omvoh. Guselkumab: Tremfya
How it works
IL-23 drives Th17 cells that fuel gut inflammation; blocking it calms the process.
Used for
- Crohn’s disease
- Ulcerative colitis
- Also psoriasis and psoriatic arthritis
Side effects
Generally well tolerated.
Full side-effect list (from the product information)
How often, from the official product information. Bold = serious.
Common 1 in 10 to 1 in 100
- Colds and sore throat
- Headache
- Tiredness
- Injection-site reactions
Uncommon 1 in 100 to 1 in 1,000
- Raised liver tests (risankizumab in Crohn’s)
- Infections
Rare 1 in 1,000 to 1 in 10,000
- Serious infections
- Allergic reactions
Get help urgently if
- Fever or signs of serious infection
- Yellow skin or dark urine
Good to know
- Before starting: screening for tuberculosis, hepatitis B and C and HIV, and catch-up vaccines.
- Avoid live vaccines (e.g. yellow fever, some shingles and travel vaccines) unless your specialist says otherwise.
- Tell your doctors before surgery, and if you get a fever or infection.
- Most biologics can be continued in pregnancy after discussion with your gastroenterologist.
Common questions
What is the difference between ustekinumab and risankizumab?
Ustekinumab blocks IL-12 and IL-23; risankizumab blocks IL-23 only. In Crohn’s after anti-TNF failure, risankizumab gave higher endoscopic remission in a head-to-head trial.
How often are the injections?
Every 4 to 8 weeks after induction, depending on the drug.
Are IL-23 biologics safe?
They have a good safety record, with low rates of serious infection, but still need screening and monitoring.
Information only. Not a recommendation or endorsement of any product. Whether a medicine suits you depends on your health and other medicines, so talk to your doctor or pharmacist. In an emergency, call 000 (Australia) or your local emergency number. From a mobile, 112 works in most countries.
More information
maladywise.com/medicines/il-12-23-biologics/